Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Human umbilical cord blood–derived mesenchymal stem cells for atopic dermatitis
FURESTEM-AD® Inj. is the world’s first stem cell therapeutic product for atopic dermatitis that targets moderate to severe atopic dermatitis patients.
Mechanism of action of FURESTEM-AD® Inj. in atopic dermatitis
FURESTEM-AD® Inj. is activated by the atopic dermatitis–associated microenvironment and secretes immunomodulatory factors, such as TGF-β1 and PGE2, thereby suppressing immune activity in the skin and reducing epidermal hyperkeratosis and pruritus.
In vitro studies on the efficacy of FURESTEM-AD® Inj. (1)
FURESTEM-AD® Inj. alleviates atopic dermatitis symptoms by reducing mast cell degranulation associated with pruritus and decreasing the secretion of TARC, which exacerbates skin inflammation.
In vitro studies on the efficacy of FURESTEM-AD® Inj. (2)
FURESTEM-AD® Inj. educed Th2 and other inflammatory immune cells, leading to alleviation of atopic dermatitis symptoms.
In vivo studies on the efficacy of FURESTEM-AD® Inj.
In an atopic dermatitis mouse model, FURESTEM-AD® Inj. was observed to reduce epidermal hyperkeratosis and decrease mast cells degranulation associated with pruritus.